GI Innovation, Inc. (KOSDAQ: 358570)

Market Cap	420.01B
Revenue	n/a
Net Income	n/a
Shares Out	44.30M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,048,827
Average Volume	569,858
Open	9,680
Previous Close	9,480
Day's Range	9,520 - 10,270
52-Week Range	7,490 - 16,340
Beta	n/a
RSI	53.02
Earnings Date	n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The company was founded in 2017 and is based in Seoul, South Kor...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 358570